Vitamin D is a secosteroidalprohormone, it can be synthesized at sufficient levels in skin, given adequate skin exposure to UV B radiation from sunlight.By directly controlling target gene expression through the Vitamin D receptor (VDR), a ligand-regulated transcription factor and member of the nuclear receptor superfamily, vitamin D modifies its biological effects. Vitamin D must undergo two hydroxylation steps in order to become the biologically active hormone 1,25-dyhydroxyvitamin D3 [1,25(OH)2D3], which communicates through the VDR, whether it is produced in the skin or consumed. In reaction to vitamin D, the hormone-bound VDR modifies target gene transcription. VDR controls autophagy's transcription at the master level. In breast cancer (BC) cells, vitamin D-activated VDR causes autophagy and an autophagic transcriptional signature.
Vitamin D comes in two different forms. Vitamin D3 (cholecalciferol) is produced in the skin and is found in oily fish and cod liver oil. Vitamin D2 (ergocalciferol) is produced by irradiating yeast and the plant sterol ergosterol. Vitamin D stands for vitamins D2 and D3.
For the treatment of psoriasis, topical medications containing active vitamin D3 (calcitriol, 1,25-dihydroxyvitaminD3, VD3) analogues, such as Tacalcitol, Calcipotriol, and Maxacalcitol, are frequently utilized.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V24327 | Maxacalcitol (22-Oxacalcitriol) | 103909-75-7 | Maxacalcitol (22-Oxacalcitriol)is a novel calcitriol analog without hypercalcemic side effects. | |
V41330 | Maxacalcitol-D6 | Maxacalcitol-D6 is the hexa-deuterated form (at the 26,27-dimethyl group) of Maxacalcitol which is a novel calcitriol analog without hypercalcemic side effects. | ||
V67833 | MeTC7 | 1817841-22-7 | MeTC7 is a vitamin D receptor (VDR) antagonist. | |
V5288 | Paricalcitol (Zemplar) | 131918-61-1 | Paricalcitol (trade name Zemplar) is a novel and potent vitamin D receptor (VDR) agonist developed by Abbott Laboratories for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure. | |
V67839 | Previtamin D3 | 1173-13-3 | Previtamin D3 is an intermediate in the preparation /synthesis of cholecalciferol (vitamin D3). | |
V67841 | Pyrocholecalciferol | 10346-43-7 | Pyrocholecalciferol A vitamin D analog generated by the photochemical conversion of 7-dehydrocholesterol (7-DHC). | |
V63206 | Secalciferol-d6 ((24R)-24,25-Dihydroxyvitamin D3-d6) | 1440957-55-0 | Secalciferol-d6 is the deuterated form of Secalciferol. | |
V5290 | Tacalcitol [1,24(R)-Dihydroxyvitamin D3] | 57333-96-7 | Tacalcitol [1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3] is a vitamin D3 analog (isomer of Vitamin D3) that promotes normal bone development by regulating calcium. | |
V12071 | TEI-9647 | 173388-20-0 | TEI-9647 (TEI9647) is a vitamin D receptor (VDR) antagonist with immunomodulatory effects. | |
V67834 | TEI-9648 | 173388-21-1 | TEI-9648 is a Vitamin D3 Lactone analogue that is a potent and specific vitamin D receptor (VDR) antagonist. | |
V81726 | VDR agonist 2 | VDR agonist 2 (compound 16i) is a VDR (vitamin D receptor) agonist that can effectively inhibit TGF-β1-induced activation of hepatic stellate cells (HSC). | ||
V5286 | Vitamin D2 (Ergocalciferol) | 50-14-6 | Vitamin D2 (Ergocalciferol; Calciferol; Ercalciol) is one form of vitamin D with a double bond on the side chain, which differentiates it from Vitamin D3 (without a double bond on the side chain). | |
V67837 | Vitamin D2-d6 (Ergocalciferol-d6; Calciferol-d6; Ercalciol-d6) | 1311259-89-8 | Vitamin D2-d6 is the deuterium labelled form of Vitamin D2. | |
V67838 | Vitamin D3-d7 (vitamin D3 d7) | 1627523-19-6 | Vitamin D3-d7 is the deuterium labelled form of Vitamin D3. | |
V5284 | Vitamin D4 | 511-28-4 | Vitamin D4 (22-Dihydroergocalciferol) is a form of vitamin D developed from fungi. | |
V78432 | Vitamin D4-d5 (22-Dihydroergocalciferol-d5) | Vitamin D4-d5 is the deuterium labelled form of Vitamin D4. |